Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?

The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are enriched with immunosuppressive myeloid cells of the innate immune system. While some immune checkpo...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-10
Main Authors: Du, Ruochen, Zhang, Jianzhong, Lukas, Rimas V, Tripathi, Shashwat, Ahrendsen, Jared T, Curran, Michael A, Dmello, Crismita, Zhang, Peng, Stupp, Roger, Rao, Ganesh, Heimberger, Amy B
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c220t-bfe9efb1596212076cba3b5bbee577e8aab8f4941921c40aa201de7b1bba59393
container_end_page
container_issue
container_start_page
container_title Neuro-oncology (Charlottesville, Va.)
container_volume
creator Du, Ruochen
Zhang, Jianzhong
Lukas, Rimas V
Tripathi, Shashwat
Ahrendsen, Jared T
Curran, Michael A
Dmello, Crismita
Zhang, Peng
Stupp, Roger
Rao, Ganesh
Heimberger, Amy B
description The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are enriched with immunosuppressive myeloid cells of the innate immune system. While some immune checkpoint targets are shared between adaptive and innate immunity, myeloid-specific checkpoints could also serve as potential therapeutics. To better understand the impact of immune checkpoint blockade on myeloid cells, we systematically summarize the current literature focusing on the direct immunological effects of PD-L1/PD-1, CD24/Siglec-10, collagen/LAIR-1, CX3CL1/CX3CR1, and CXCL10/CXCR3. By synthesizing the molecular mechanisms and the translational implications, we aim to prioritize agents in this category of therapeutics for glioblastoma.
doi_str_mv 10.1093/neuonc/noae193
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3118834511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3118834511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c220t-bfe9efb1596212076cba3b5bbee577e8aab8f4941921c40aa201de7b1bba59393</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0Eory2LJGXbNJ67DiJVwghXlIlNrCObHdSDH6UOEHq39PSwmpGmnOvRoeQS2BTYErMIo4p2llMGkGJA3ICkotCNlV1-LvzopFQT8hpzh-McZAVHJOJUCWvBa9OSHjONKTF6PXgUqSpoy6EMSK172g_V8nFIdPNYeldMl7nIQVduNg5P_SbSFzSsEaf3IJa9D5TTb-dNh7p8I69XuE4OEvzlsXl-uacHHXaZ7zYzzPy9nD_evdUzF8en-9u54XlnA2F6VBhZ0CqigNndWWNFkYagyjrGhutTdOVqgTFwZZMa85ggbUBY7RUQokzcr3rXfXpa8Q8tMHl7YM6YhpzKwCaRpQSYINOd6jtU849du2qd0H36xZYu1Xc7hS3e8WbwNW-ezQBF__4n1PxAydBfQs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118834511</pqid></control><display><type>article</type><title>Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?</title><source>Oxford Journals Online</source><creator>Du, Ruochen ; Zhang, Jianzhong ; Lukas, Rimas V ; Tripathi, Shashwat ; Ahrendsen, Jared T ; Curran, Michael A ; Dmello, Crismita ; Zhang, Peng ; Stupp, Roger ; Rao, Ganesh ; Heimberger, Amy B</creator><creatorcontrib>Du, Ruochen ; Zhang, Jianzhong ; Lukas, Rimas V ; Tripathi, Shashwat ; Ahrendsen, Jared T ; Curran, Michael A ; Dmello, Crismita ; Zhang, Peng ; Stupp, Roger ; Rao, Ganesh ; Heimberger, Amy B</creatorcontrib><description>The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are enriched with immunosuppressive myeloid cells of the innate immune system. While some immune checkpoint targets are shared between adaptive and innate immunity, myeloid-specific checkpoints could also serve as potential therapeutics. To better understand the impact of immune checkpoint blockade on myeloid cells, we systematically summarize the current literature focusing on the direct immunological effects of PD-L1/PD-1, CD24/Siglec-10, collagen/LAIR-1, CX3CL1/CX3CR1, and CXCL10/CXCR3. By synthesizing the molecular mechanisms and the translational implications, we aim to prioritize agents in this category of therapeutics for glioblastoma.</description><identifier>ISSN: 1522-8517</identifier><identifier>ISSN: 1523-5866</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae193</identifier><identifier>PMID: 39427326</identifier><language>eng</language><publisher>England</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-10</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c220t-bfe9efb1596212076cba3b5bbee577e8aab8f4941921c40aa201de7b1bba59393</cites><orcidid>0000-0002-5483-3118 ; 0000-0002-9970-8695 ; 0000-0002-9352-5396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39427326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Du, Ruochen</creatorcontrib><creatorcontrib>Zhang, Jianzhong</creatorcontrib><creatorcontrib>Lukas, Rimas V</creatorcontrib><creatorcontrib>Tripathi, Shashwat</creatorcontrib><creatorcontrib>Ahrendsen, Jared T</creatorcontrib><creatorcontrib>Curran, Michael A</creatorcontrib><creatorcontrib>Dmello, Crismita</creatorcontrib><creatorcontrib>Zhang, Peng</creatorcontrib><creatorcontrib>Stupp, Roger</creatorcontrib><creatorcontrib>Rao, Ganesh</creatorcontrib><creatorcontrib>Heimberger, Amy B</creatorcontrib><title>Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?</title><title>Neuro-oncology (Charlottesville, Va.)</title><addtitle>Neuro Oncol</addtitle><description>The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are enriched with immunosuppressive myeloid cells of the innate immune system. While some immune checkpoint targets are shared between adaptive and innate immunity, myeloid-specific checkpoints could also serve as potential therapeutics. To better understand the impact of immune checkpoint blockade on myeloid cells, we systematically summarize the current literature focusing on the direct immunological effects of PD-L1/PD-1, CD24/Siglec-10, collagen/LAIR-1, CX3CL1/CX3CR1, and CXCL10/CXCR3. By synthesizing the molecular mechanisms and the translational implications, we aim to prioritize agents in this category of therapeutics for glioblastoma.</description><issn>1522-8517</issn><issn>1523-5866</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0Eory2LJGXbNJ67DiJVwghXlIlNrCObHdSDH6UOEHq39PSwmpGmnOvRoeQS2BTYErMIo4p2llMGkGJA3ICkotCNlV1-LvzopFQT8hpzh-McZAVHJOJUCWvBa9OSHjONKTF6PXgUqSpoy6EMSK172g_V8nFIdPNYeldMl7nIQVduNg5P_SbSFzSsEaf3IJa9D5TTb-dNh7p8I69XuE4OEvzlsXl-uacHHXaZ7zYzzPy9nD_evdUzF8en-9u54XlnA2F6VBhZ0CqigNndWWNFkYagyjrGhutTdOVqgTFwZZMa85ggbUBY7RUQokzcr3rXfXpa8Q8tMHl7YM6YhpzKwCaRpQSYINOd6jtU849du2qd0H36xZYu1Xc7hS3e8WbwNW-ezQBF__4n1PxAydBfQs</recordid><startdate>20241019</startdate><enddate>20241019</enddate><creator>Du, Ruochen</creator><creator>Zhang, Jianzhong</creator><creator>Lukas, Rimas V</creator><creator>Tripathi, Shashwat</creator><creator>Ahrendsen, Jared T</creator><creator>Curran, Michael A</creator><creator>Dmello, Crismita</creator><creator>Zhang, Peng</creator><creator>Stupp, Roger</creator><creator>Rao, Ganesh</creator><creator>Heimberger, Amy B</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5483-3118</orcidid><orcidid>https://orcid.org/0000-0002-9970-8695</orcidid><orcidid>https://orcid.org/0000-0002-9352-5396</orcidid></search><sort><creationdate>20241019</creationdate><title>Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?</title><author>Du, Ruochen ; Zhang, Jianzhong ; Lukas, Rimas V ; Tripathi, Shashwat ; Ahrendsen, Jared T ; Curran, Michael A ; Dmello, Crismita ; Zhang, Peng ; Stupp, Roger ; Rao, Ganesh ; Heimberger, Amy B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c220t-bfe9efb1596212076cba3b5bbee577e8aab8f4941921c40aa201de7b1bba59393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Du, Ruochen</creatorcontrib><creatorcontrib>Zhang, Jianzhong</creatorcontrib><creatorcontrib>Lukas, Rimas V</creatorcontrib><creatorcontrib>Tripathi, Shashwat</creatorcontrib><creatorcontrib>Ahrendsen, Jared T</creatorcontrib><creatorcontrib>Curran, Michael A</creatorcontrib><creatorcontrib>Dmello, Crismita</creatorcontrib><creatorcontrib>Zhang, Peng</creatorcontrib><creatorcontrib>Stupp, Roger</creatorcontrib><creatorcontrib>Rao, Ganesh</creatorcontrib><creatorcontrib>Heimberger, Amy B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Du, Ruochen</au><au>Zhang, Jianzhong</au><au>Lukas, Rimas V</au><au>Tripathi, Shashwat</au><au>Ahrendsen, Jared T</au><au>Curran, Michael A</au><au>Dmello, Crismita</au><au>Zhang, Peng</au><au>Stupp, Roger</au><au>Rao, Ganesh</au><au>Heimberger, Amy B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><addtitle>Neuro Oncol</addtitle><date>2024-10-19</date><risdate>2024</risdate><issn>1522-8517</issn><issn>1523-5866</issn><eissn>1523-5866</eissn><abstract>The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are enriched with immunosuppressive myeloid cells of the innate immune system. While some immune checkpoint targets are shared between adaptive and innate immunity, myeloid-specific checkpoints could also serve as potential therapeutics. To better understand the impact of immune checkpoint blockade on myeloid cells, we systematically summarize the current literature focusing on the direct immunological effects of PD-L1/PD-1, CD24/Siglec-10, collagen/LAIR-1, CX3CL1/CX3CR1, and CXCL10/CXCR3. By synthesizing the molecular mechanisms and the translational implications, we aim to prioritize agents in this category of therapeutics for glioblastoma.</abstract><cop>England</cop><pmid>39427326</pmid><doi>10.1093/neuonc/noae193</doi><orcidid>https://orcid.org/0000-0002-5483-3118</orcidid><orcidid>https://orcid.org/0000-0002-9970-8695</orcidid><orcidid>https://orcid.org/0000-0002-9352-5396</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-10
issn 1522-8517
1523-5866
1523-5866
language eng
recordid cdi_proquest_miscellaneous_3118834511
source Oxford Journals Online
title Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A54%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20modulation%20of%20immune%20checkpoints%20on%20glioblastoma-infiltrating%20myeloid%20cells%20a%20viable%20therapeutic%20strategy?&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Du,%20Ruochen&rft.date=2024-10-19&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae193&rft_dat=%3Cproquest_cross%3E3118834511%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c220t-bfe9efb1596212076cba3b5bbee577e8aab8f4941921c40aa201de7b1bba59393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3118834511&rft_id=info:pmid/39427326&rfr_iscdi=true